http://www.law360.com/ Latest articles for organization: Pfizer Copyright 2009 Portfolio Media, Inc. en-US http://www.law360.com/images/headings/logo.gif http://www.law360.com/ http://www.law360.com/articles/132933 Plaintiffs have dropped their putative class action accusing Pfizer Inc. of fraudulently marketing Lipitor by covering up certain side effects and misrepresenting the cholesterol drug's efficacy in some patient groups. http://www.law360.com/articles/132933 http://www.law360.com/articles/132433 While the verdict officially remains under wraps, word is spreading that a Pennsylvania jury has ordered Pfizer Inc. to fork over $75 million in punitive damages to a woman who developed invasive breast cancer after she began taking the popular menopause drug Prempro. http://www.law360.com/articles/132433 http://www.law360.com/articles/132248 The U.S. Department of Commerce is lauding the White House's recent pick of Suresh Kumar to the post of director general of the U.S. and Foreign Commercial Service. http://www.law360.com/articles/132248 http://www.law360.com/articles/131834 The U.S. Supreme Court has asked Solicitor General Elena Kagan to weigh in on the Alien Tort Statute in a case involving pharmaceutical giant Pfizer Inc.'s medical experiments in Nigeria. http://www.law360.com/articles/131834 http://www.law360.com/articles/131863 A federal appeals court has ruled that a judge rightly threw out a $27 million award to a woman who claimed Wyeth and a Pfizer Inc. subsidiary failed to warn about the cancer risk of their controversial hormone replacement treatment because of expert testimony the judge said should not have been allowed. http://www.law360.com/articles/131863 http://www.law360.com/articles/131501 Plaintiffs in a long-running dispute over pension plans for employees of agricultural giant Monsanto Corp. and two spinoff health care companies have appealed a district court decision tossing their class action claims that the pension plans improperly calculated their benefits in violation of federal law. http://www.law360.com/articles/131501 http://www.law360.com/articles/131483 Merck & Co.’s proposed $41.1 billion acquisition of Schering-Plough Corp. has gained approval from U.S. antitrust regulators on the condition that both companies shed certain assets. http://www.law360.com/articles/131483 http://www.law360.com/articles/131152 Pfizer Inc. is again trying to fend off a lawsuit by a group of California pharmacies and pharmacists claiming the drugmaker's $68 billion buyout of rival Wyeth will eliminate competition and stifle innovation in the U.S. prescription drug market. http://www.law360.com/articles/131152 http://www.law360.com/articles/131288 A magistrate judge in a contract and trade secrets suit brought by Brigham Young University and a professor who claims he had a key role in discovering an enzyme that led to the development of Bextra and Celebrex has sanctioned the drugs' maker, a move the judge said she hoped would entice Pfizer Inc. to comply with its discovery obligations. http://www.law360.com/articles/131288 http://www.law360.com/articles/131010 A British charitable trust has slapped Amgen Inc. and Pfizer Inc. subsidiary Wyeth with a lawsuit over the lucrative rheumatoid arthritis drug Enbrel, accusing the two defendants — which co-market Enbrel in the U.S. — of willfully infringing a single patent and ignoring demands for royalty payments. http://www.law360.com/articles/131010 http://www.law360.com/articles/130536 In a one-two punch to Pfizer Inc., a Philadelphia jury has reportedly awarded punitive damages in addition to $3.7 million in compensatory damages to a woman who developed invasive breast cancer after she began taking Prempro, which is made by the company’s Wyeth unit. http://www.law360.com/articles/130536 http://www.law360.com/articles/130011 EU antitrust regulators have cleared Merck & Co.’s proposed $41.1 billion acquisition of Schering-Plough Corp., a move that will make it the second-largest prescription drug company in the world. http://www.law360.com/articles/130011 http://www.law360.com/articles/123719 This article discusses various aspects of Chinese intellectual property policy and progress as a consequence of the World Trade Organization-driven and, more recently, innovation-driven history of Chinese IP law, say Dr. Qian Huang and Paul Devinsky of McDermott Will & Emery LLP. http://www.law360.com/articles/123719 http://www.law360.com/articles/123120 One of the most challenging problems in international trade law today is that many clients must operate in a manner that serves the seemingly inconsistent regulations of several countries, says Stanley U. North III, a partner in LeClairRyan's corporate group who specializes in international trade. http://www.law360.com/articles/123120 http://www.law360.com/articles/128930 A federal court has levied a record $1.3 billion criminal fine — the largest ever imposed in the U.S. — against Pfizer Inc. subsidiary Pharmacia & Upjohn Co. Inc. for fraudulently misbranding its anti-inflammatory drug Bextra. http://www.law360.com/articles/128930 http://www.law360.com/articles/128844 A group of California pharmacies and pharmacists has picked up the sword again in its fight to block Pfizer Inc.’s proposed $68 billion buyout of rival Wyeth, filing an amended complaint after a judge ruled the plaintiffs had failed to support their claims that the merger will eliminate competition and stifle innovation in the U.S. prescription drug market. http://www.law360.com/articles/128844 http://www.law360.com/articles/120566 The Pfizer-Wyeth and Merck-Schering-Plough deals included terms — a financing condition in the Pfizer deal and reverse breakup fees in both — usually relegated to the private equity sphere. And while the provisions may not become commonplace in strategic deals, they will almost certainly show up in negotiations, mergers and acquisitions professionals said. http://www.law360.com/articles/120566 http://www.law360.com/articles/128564 Skandia Life Insurance Co. Ltd. has become the latest party to request lead plaintiff status in a consolidated derivative lawsuit accusing Pfizer Inc. executives of harming the company by promoting prescription drugs for unapproved off-label uses. http://www.law360.com/articles/128564 http://www.law360.com/articles/128347 Pfizer Inc.'s $68 billion acquisition of Wyeth Inc. will close Thursday after receiving clearance from the Federal Trade Commission. http://www.law360.com/articles/128347 http://www.law360.com/articles/124648 In the wake of a financial crisis that crammed courtrooms full of the debris from failed deals, experts say they expect reverse breakup fees, the fees a buyer pays to a seller if a deal goes bust, to creep upward as sellers push for more security. http://www.law360.com/articles/124648